富智康集團(02038.HK):向公司一家間接全資附屬公司注資5億元新台幣
格隆匯4月29日丨富智康集團(02038.HK)公佈,分別於2019年5月23日、2019年7月19日、2020年1月17日及2020年4月29日,公司於英屬維爾京羣島註冊成立的間接全資附屬公司均威已向其於台灣註冊成立的直接全資附屬公司富智捷進行若干次注資,總金額合共新台幣5億元作多種用途,包括作為額外營運資金。
緊隨該等注資後,富智捷已發行股本總額已增至新台幣5億元,分為每股面值新台幣10元的5000萬股普通股,代表由均威持有的富智捷全部已發行股本。富智捷的主要業務為人工智能車用自動駕駛軟件及其系統的研發和銷售。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.